NASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis $0.69 0.00 (-0.55%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$0.69 0.00 (-0.03%) As of 11/16/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Pliant Therapeutics Stock (NASDAQ:PLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pliant Therapeutics alerts:Sign Up Key Stats Today's Range$0.66▼$0.7150-Day Range$0.69▼$1.1752-Week Range$0.66▼$1.72Volume999,035 shsAverage Volume304,361 shsMarket Capitalization$42.92 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Pliant Therapeutics is a biopharmaceutical company focused on developing medicines for fibrotic diseases, in which excess scar tissue can impair the function of organs. The company’s research centers on integrins, proteins involved in processes such as tissue repair and fibrosis. Its investigational programs have included bexotegrast, an oral drug designed to inhibit the αvβ6 and αvβ1 integrins and studied for conditions including idiopathic pulmonary fibrosis. Pliant has also pursued other drug candidates targeting fibrotic disease pathways. These medicines are investigational and are not approved treatments. Based in South San Francisco, California, Pliant has conducted clinical research in the United States and other countries. Its work is focused on drug discovery and development rather than providing medical products or services directly to patients.AI Generated. May Contain Errors. Read More Pliant Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScorePLRX MarketRank™: 1.466480446925 of 5 starsPliant Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 776th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingPliant Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialPliant Therapeutics has a consensus price target of $3.00, representing about 332.8% upside from its current price of $0.69.Amount of Analyst CoveragePliant Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Pliant Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($1.42) to ($1.53) per share.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.64% of the float of Pliant Therapeutics has been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 5.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.15 News SentimentPliant Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Pliant Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.74% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLRX Stock News HeadlinesPliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsNovember 12, 2026 | globenewswire.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date. | Paradigm Press (Ad)Pliant Therapeutics (NASDAQ:PLRX) versus Arbutus Biopharma (NASDAQ:ABUS) Head-To-Head ComparisonNovember 10, 2026 | americanbankingnews.comPliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of CancerNovember 9, 2026 | globenewswire.comPliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to "Sell"November 7, 2026 | americanbankingnews.comPliant Therapeutics, Inc. Announces Presentations Of PLN-101095 At The 2026 Annual Meeting Of The Society For Immunotherapy Of CancerOctober 29, 2026 | marketscreener.comMPliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of CancerOctober 29, 2026 | marketscreener.comMSee More Headlines PLRX Stock Analysis - Frequently Asked Questions How have PLRX shares performed this year? Pliant Therapeutics' stock was trading at $1.22 on January 1st, 2026. Since then, PLRX stock has decreased by 43.2% and is now trading at $0.6932. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted its earnings results on Thursday, November, 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $135 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 9,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Top institutional investors of Pliant Therapeutics include State Street Corp (0.41%) and Empowered Funds LLC (0.13%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull, Mike Ouimette and Minnie Kuo. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include Cabaletta Bio (CABA), NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Black Diamond Therapeutics (BDTX), ADC Therapeutics (ADCT) and Gossamer Bio (GOSS). Company Calendar Last Earnings11/12/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PLRX's financial health is in the Red zone, according to TradeSmith. PLRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PLRX CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees49Year Founded2016Price Target and Rating Average Price Target for Pliant Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+332.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.34 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.84% Return on Assets-43.00% Debt Debt-to-Equity RatioN/A Current Ratio9.90 Quick Ratio9.90 Sales & Book Value Annual Sales$1.58 million Price / Sales27.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book0.23Miscellaneous Outstanding Shares61,920,000Free Float56,510,000Market Cap$42.92 million OptionableOptionable Beta1.36 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PLRX) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.